title: Subtype-specific therapy for DLBCL: are we there yet?
abstract: In this issue of Blood, Offner et al report the results of LYM-2034, a phase 2 multinational trial in which 164 patients with nongerminal center B-cell–like diffuse large B-cell lymphoma (non-GCB DLBCL) were randomized to receive rituximab, cyclophosphamide, adriamycin, prednisone, and either vincristine (R-CHOP) or bortezomib (VR-CAP). DLBCL, previously recognized as a single disease entity, represents a heterogeneous group of diseases.
authors.affiliation: FOX CHASE CANCER CENTER.
authors.forename: Nadia
authors.identifier: http://orcid.org/0000-0002-9683-5779
authors.initials: N
authors.lastname: Khan
authors.affiliation: FOX CHASE CANCER CENTER.
authors.forename: Richard I
authors.initials: RI
authors.lastname: Fisher
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality*; D008297:Male